SEARCH

SEARCH BY CITATION

References

  • Brorson K, Swann P, Brown J, Wilcox B, Shaprio M. 2005. Considerations for developing biopharmaceuticals: The FDA perspective. In: KnableinJ, editor. Modern Biopharmaceuticals. Weinheim, Germany: Wiley-VCH.
  • Food and Drug Administration. 1987. Guideline on General Principles of Process Validation. (http://www.fda.gov/cder/guidance).
  • Food and Drug Administration. 2004. PAT—Framework for InnovativePharmaceutical Development, Manufacturing, and Quality Assurance. 2004. (http://www.fda.gov/cder/guidance).
  • Hanson MA, Ge X, Kostov Y, Brorson KA, Moreira AR, Rao G. Comparisons of optical pH and Dissolved Oxygen sensors with traditional electrochemical probes during mammalian cell culture. 2007. Biotechnol Bioeng 97: 833841.
  • Harms J, Wang X, Kim T, Yang X, Rathore AS. 2008. Defining process design space for biotech products: Case Study of Pichia pastoris Fermentation. Biotech Prog 24: 655662.
  • Hermann R, Lehmann M, Büchs J. 2002. Characterization of gas–liquid mass transfer phenomena in microtiter plates. Biotechnol Bioeng 81: 178186.
  • Humphrey AE. 1998. Shake flask to fermentor: what have we learned? Biotech Prog 14: 37.
  • Isett K, George H, Herber W, Amanullah A. 2007. Twenty-four-well plate miniature bioreactor high-throughput system: Assessment for microbial cultivations. Biotechnol Bioeng 98: 10171028.
  • Junker BH, Wang HY. 2006. Bioprocess monitoring and computer control: Key roots of the current PAT initiative. Biotechnol Bioeng 95: 226261.
  • Kostov Y, Harms P, Randers-Eichhorn L, Rao G. 2001. Low-cost microbioreactor for high-throughput bioprocessing. Biotechnol Bioeng 72: 346352.
  • Markovic I. 2006. Challenges associated with extractable and/or leachable substances in therapeutic biologic protein products. Am Pharm Rev. October 2006.
  • Mittelman MW, White DC. 1990. The role of biofilms in contamination of process fluids by biological particulates. In: MittalKL, editor. Particles in gases and liquids, Vol. 2. New York: Plenum Press. pp 3350.
  • Q7. Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. 2000 (http://www.ich.org).
  • Q8: ICH. Harmonized Tripartite Guideline on Pharmaceutical Development. November 10, 2005a (http://www.ich.org).
  • Q9: ICH. Harmonized Tripartite Guideline on Quality Risk Management. November 9, 2005b (http://www.ich.org).
  • Q5E: ICH. Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. 2005c (http://www.ich.org).
  • Q8 Annexe, ICH Harmonized Tripartite Guideline on Pharmaceutical Development. Current Step 2 version. November 1, 2007 (http://www.ich.org).
  • Rathore AS, Sharma A, Chilin D. 2006. Applying process analytical technology to biotech unit operations. BioPharm. August issue. 4857.
  • Rathore AS, Johnson R, Yu O, Kirdar AO, Annamalai A, Ahuja S, Ram K. 2007. Applications of multivariate data analysis in biotech processing. BioPharm Intl. October issue.
  • US Government Pandemic Flu Report, 2007. (http://www.pandemicflu.gov/).
  • Zanzotto A, Szita N, Boccazzi P, Lessard P, Sinskey AJ, Jensen KF. 2004. Membrane-aerated microbioreactor for high-throughput bioprocessing. Biotechnol Bioeng 87: 243254.